|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4184 | |
| A61K 9/00 | |||
| A61K 9/08 | |||
| A61P 27/06 |
| (11) | Patento numeris | 2525793 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11702342.4 |
| Europos patento paraiškos padavimo data | 2011-01-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-11-28 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-09-05 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/022001 |
| Data | 2011-01-21 |
| (87) | Numeris | WO 2011/091225 |
| Data | 2011-07-28 |
| (30) | Numeris | Data | Šalis |
| 296912 P | 2010-01-21 | US |
| (72) |
DONELLO, John E., US
GIL, Daniel W., US
DIBAS, Mohammed I., US
|
| (73) |
ALLERGAN, INC.,
2525 Dupont Drive, Irvine, CA 92612,
US
|
| (54) | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
| Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |